SLC25A25 Antibody

What is SLC25A25 and what is its function in cellular metabolism?

SLC25A25 (Solute Carrier Family 25 Member 25) functions as a calcium-dependent mitochondrial solute carrier that shuttles metabolites, nucleotides, and cofactors through the mitochondrial inner membrane. It primarily acts as an ATP-Mg/Pi exchanger, mediating the transport of Mg-ATP in exchange for phosphate, thereby catalyzing the net uptake or efflux of adenine nucleotides into or from the mitochondria . This protein plays a crucial role in energy metabolism and mitochondrial function. With a calculated molecular weight of approximately 52.7 kDa, SLC25A25 represents an important target for research into mitochondrial biology and metabolic disorders .

What types of SLC25A25 antibodies are available for research applications?

Research-grade SLC25A25 antibodies are available in several formats with varying specifications:

Researchers should select antibodies based on their specific experimental needs, considering factors such as host species, clonality, epitope region, and validated applications .

How should I optimize Western blot protocols for SLC25A25 detection?

For optimal Western blot detection of SLC25A25, follow these methodological considerations:

• Sample preparation: Extract mitochondrial fractions when possible as SLC25A25 is a mitochondrial carrier protein. Use appropriate lysis buffers containing protease inhibitors.

• Antibody dilution: Start with a 1:1000 dilution for Western blot applications as recommended for antibodies like A09109 . Optimization may be required based on your specific antibody and sample.

• Controls: Include positive controls such as U-937 cell line or rat cerebellum tissue lysates, which have been validated for SLC25A25 detection .

• Loading amount: Use approximately 35μg of protein per lane as validated in previous experiments .

• Detection system: Use appropriate secondary antibodies based on your primary antibody host species (anti-rabbit for rabbit-derived antibodies; anti-mouse for mouse-derived antibodies).

• Expected band size: Look for a band at approximately 52.7 kDa, corresponding to the calculated molecular weight of SLC25A25 .

The validation images from antibody suppliers can provide reference points for expected results and troubleshooting guides .

What considerations should be made when selecting between polyclonal and monoclonal SLC25A25 antibodies?

The selection between polyclonal and monoclonal SLC25A25 antibodies depends on specific experimental requirements:

Polyclonal antibodies (e.g., ABIN635360, A09109):

• Advantages: Higher sensitivity due to recognition of multiple epitopes, more robust to protein denaturation, generally less expensive

• Best applications: Initial protein detection, immunoprecipitation, IHC studies

• Suitable for: Cross-species reactivity studies (e.g., studies involving human, rat, mouse, and other species)

Monoclonal antibodies (e.g., ABIN530274 clone 4D8):

• Advantages: Higher specificity, reduced batch-to-batch variation, consistent results

• Best applications: Precise epitope targeting, distinguishing between protein isoforms

• Considerations: More limited cross-species reactivity (e.g., human-specific)

For SLC25A25 research, consider using monoclonal antibodies when absolute specificity is required or when distinguishing between different SLC25 family members. Use polyclonal antibodies when maximum sensitivity is needed or when studying SLC25A25 across multiple species .

How can I validate SLC25A25 antibody specificity for my particular experimental system?

Validating antibody specificity is crucial for reliable SLC25A25 research. Implement these methodological approaches:

• Positive controls: Use tissues/cells known to express SLC25A25, such as U-937 cell lines or rat cerebellum tissue, which have been validated in previous studies .

• Negative controls: Consider:

  • Secondary antibody-only controls

  • Pre-immune serum (for polyclonal antibodies)

  • Isotype controls (for monoclonal antibodies)

• Blocking peptide validation: Use the synthetic peptide that was used as the immunogen (e.g., the KLH-conjugated peptide from amino acids 63-93 for antibody A09109). Pre-incubate the antibody with an excess of this blocking peptide before application to your samples. Signal disappearance confirms specificity .

• Genetic validation:

  • SLC25A25 knockdown/knockout samples

  • Overexpression systems with tagged SLC25A25

• Multiple antibody approach: Use antibodies targeting different epitopes of SLC25A25 (e.g., N-terminal vs. internal region) and compare the results .

• Cross-reactivity assessment: Test antibody against related SLC25 family members to ensure it doesn't cross-react with structurally similar proteins.

Documentation of these validation steps significantly strengthens the credibility of your SLC25A25 research findings.

What are the optimal approaches for studying SLC25A25 localization and expression patterns in different tissues?

For comprehensive analysis of SLC25A25 localization and expression patterns:

• Immunohistochemistry (IHC):

  • Use paraffin-embedded tissue sections with antibodies validated for IHC-P (e.g., A09109)

  • Recommended dilution: 1:25 for IHC applications

  • Detection system: biotinylated secondary antibody followed by DAB staining

  • Validated tissues: Human skeletal muscle has shown specific staining

• Immunofluorescence (IF):

  • Use antibodies validated for IF applications

  • Co-stain with mitochondrial markers (e.g., TOMM20, MitoTracker) to confirm mitochondrial localization

  • Use confocal microscopy for precise subcellular localization

• Tissue panel analysis:

  • Compare expression levels across tissues to identify high-expression regions

  • Consider using tissue microarrays for high-throughput screening

• Species comparison:

  • Use antibodies with cross-species reactivity (e.g., ABIN635360) to compare expression patterns across species including human, rat, mouse, and others

• Quantitative approaches:

  • Complement immunostaining with qPCR and Western blot for quantitative expression data

  • Use image analysis software to quantify staining intensity in IHC/IF experiments

These methodologies can be combined to provide a comprehensive understanding of SLC25A25 expression patterns in normal physiology and disease states.

How can I address weak or inconsistent SLC25A25 signal in Western blot experiments?

When encountering weak or inconsistent SLC25A25 signals in Western blot applications:

• Sample preparation optimization:

  • Ensure complete protein extraction with mitochondria-specific lysis buffers

  • Prevent protein degradation by using fresh protease inhibitors

  • Optimize sample loading (35μg protein/lane is recommended based on validation studies)

• Antibody optimization:

  • Test different antibody concentrations beyond the recommended 1:1000 dilution

  • Increase primary antibody incubation time (overnight at 4°C)

  • Try different antibodies targeting distinct epitopes of SLC25A25

• Transfer efficiency improvements:

  • Optimize transfer conditions for proteins in the 50-55 kDa range

  • Consider using PVDF membranes for better protein retention

  • Verify transfer efficiency with reversible protein stains (Ponceau S)

• Detection system enhancement:

  • Use high-sensitivity ECL substrates

  • Consider signal amplification systems

  • Optimize exposure times based on signal intensity

• Buffer system modifications:

  • Adjust blocking conditions (BSA vs. milk, concentration, time)

  • Optimize washing steps (TBST vs. PBST, washing duration)

If these approaches fail to improve signal, consider alternative detection methods such as immunoprecipitation followed by Western blot, which can enhance sensitivity for low-abundance proteins.

What strategies can address cross-reactivity or background issues when using SLC25A25 antibodies?

To minimize cross-reactivity and background issues with SLC25A25 antibodies:

• Antibody selection considerations:

  • For highest specificity, consider monoclonal antibodies like ABIN530274 (clone 4D8)

  • For polyclonal antibodies, select those with affinity purification (like ABIN635360)

• Blocking optimization:

  • Test different blocking agents (BSA, milk, commercial blockers)

  • Extend blocking time (2-3 hours at room temperature)

  • Include 0.1-0.3% Triton X-100 in blocking solution to reduce non-specific binding

• Antibody dilution optimization:

  • Prepare antibodies in fresh blocking buffer

  • Increase dilution beyond recommended starting points

  • Consider pre-adsorption with proteins from non-relevant species

• Washing protocol enhancement:

  • Increase number and duration of washes

  • Use higher detergent concentration in wash buffers

  • Consider adding low salt concentration to reduce ionic interactions

• Signal specificity confirmation:

  • Use blocking peptides to confirm signal specificity (available for antibodies like A09109)

  • Run appropriate negative controls in parallel

• Cross-adsorption techniques:

  • Pre-incubate antibodies with tissues/lysates from species or tissues not expressing the target

  • Use immunoaffinity purification to remove cross-reactive antibodies

Implementing these strategies should significantly improve signal-to-noise ratio and specificity in your SLC25A25 experiments.

How can SLC25A25 antibodies be utilized in studying mitochondrial dysfunction in metabolic disorders?

SLC25A25 antibodies can provide valuable insights into mitochondrial dysfunction in metabolic disorders through several research approaches:

• Expression level analysis:

  • Compare SLC25A25 expression between healthy and diseased tissues using Western blot

  • Quantify expression changes in response to metabolic stress conditions

  • Correlate expression levels with markers of mitochondrial function

• Localization studies in disease models:

  • Use immunofluorescence with confocal microscopy to assess SLC25A25 localization changes

  • Co-localize with other mitochondrial markers to evaluate mitochondrial integrity

  • Examine redistribution patterns in response to cellular stress

• Protein interaction studies:

  • Utilize co-immunoprecipitation with SLC25A25 antibodies to identify binding partners

  • Investigate changes in protein interactions under pathological conditions

  • Connect SLC25A25 function to broader metabolic pathway alterations

• Functional correlation studies:

  • Combine SLC25A25 expression analysis with ATP/ADP ratio measurements

  • Correlate SLC25A25 levels with calcium flux in mitochondria

  • Examine the relationship between SLC25A25 expression and mitochondrial membrane potential

• Post-translational modification assessment:

  • Detect changes in phosphorylation or other modifications using specific antibodies

  • Determine how these modifications affect SLC25A25 function in disease states

Given SLC25A25's role as an ATP-Mg/Pi exchanger mediating adenine nucleotide transport in mitochondria , these approaches can illuminate its contribution to bioenergetic disruptions in metabolic disorders.

What are the considerations for using SLC25A25 antibodies in co-immunoprecipitation and chromatin immunoprecipitation experiments?

When designing co-immunoprecipitation (Co-IP) or chromatin immunoprecipitation (ChIP) experiments with SLC25A25 antibodies:

For Co-IP experiments:

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation applications

  • Polyclonal antibodies like ABIN635360 are often more effective for Co-IP due to their recognition of multiple epitopes

  • Consider using antibodies targeting regions not involved in protein-protein interactions

• Lysis conditions:

  • Use gentle lysis buffers to maintain protein-protein interactions (e.g., NP-40 or Triton X-100 based)

  • Include protease and phosphatase inhibitors to preserve native interactions

  • Optimize salt concentration to maintain specific interactions while reducing background

• Cross-linking considerations:

  • For transient interactions, consider reversible cross-linking with DSP or formaldehyde

  • Test different cross-linker concentrations and durations

• Technical approaches:

  • Use pre-clearing steps with appropriate control IgG to reduce non-specific binding

  • Consider magnetic beads over agarose for gentler handling and lower background

  • Include appropriate negative controls (non-immune IgG, lysates from cells not expressing SLC25A25)

For ChIP experiments:
While SLC25A25 is not typically a DNA-binding protein, if investigating its potential interaction with chromatin components:

• Cross-linking optimization:

  • Use higher formaldehyde concentrations (1-2%) due to potential indirect association with chromatin

  • Consider dual cross-linking approaches (DSG followed by formaldehyde)

• Sonication parameters:

  • Optimize sonication conditions to generate 200-500bp DNA fragments

  • Verify fragmentation efficiency by agarose gel electrophoresis

• Controls:

  • Include input controls, IgG controls, and positive controls (antibodies against known chromatin-associated proteins)

• Validation approaches:

  • Confirm SLC25A25 association with chromatin components using alternative methods

  • Consider sequential ChIP to identify co-occupancy with known transcription factors

These considerations will maximize experimental success while minimizing artifacts in interaction studies involving SLC25A25.

How do SLC25A25 antibodies perform across different species, and what validation is required for cross-species applications?

SLC25A25 antibodies show varying degrees of cross-species reactivity, which requires careful validation:

Cross-species reactivity patterns:

Cross-species validation approaches:

• Sequence homology assessment:

  • Analyze epitope conservation across species using sequence alignment tools

  • Higher epitope conservation typically predicts better cross-reactivity

• Step-wise validation:

  • Begin with Western blot validation in each species

  • Confirm expected molecular weight (~52.7 kDa)

  • Verify signal reduction/elimination with blocking peptides or knockdown samples

• Positive controls for each species:

  • Use tissues known to express SLC25A25 (e.g., skeletal muscle, cerebellum)

  • Include recombinant SLC25A25 from the species of interest when available

• Specificity controls:

  • Compare staining patterns across species to confirm consistent subcellular localization

  • Validate with alternative detection methods (qPCR, mass spectrometry)

• Dilution optimization:

  • Antibody concentration requirements may vary between species

  • Perform dilution series for each new species application

For maximum confidence in cross-species applications, select antibodies like ABIN635360 with demonstrated broad reactivity across multiple species , and always perform species-specific validation before proceeding with full experiments.

Are there established protocols for differentiating between SLC25A25 and other closely related mitochondrial carrier proteins?

Distinguishing SLC25A25 from other mitochondrial carrier family members requires specialized experimental approaches:

• Antibody epitope selection:

  • Choose antibodies targeting unique regions of SLC25A25 not conserved in other family members

  • Antibodies against the N-terminal region (e.g., A09109) often provide better discrimination, as this region typically shows lower conservation among SLC25 family members

• Comparative analysis protocol:

  • Run parallel Western blots with antibodies against multiple SLC25 family members

  • Compare migration patterns on SDS-PAGE to identify size differences

  • Use recombinant proteins of different SLC25 family members as positive controls

• Immunodepletion approach:

  • Sequentially deplete lysates with antibodies against different SLC25 family members

  • Analyze remaining proteins to confirm specificity

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm identity through unique peptide signatures

• Genetic validation strategies:

  • Use cells with CRISPR/Cas9 knockout of specific SLC25 family members

  • Create cell lines with tagged versions of different SLC25 proteins

  • Employ siRNA knockdown with family member-specific sequences

• Functional discrimination:

  • Combine immunodetection with functional assays specific to SLC25A25's ATP-Mg/Pi exchange activity

  • Measure calcium-dependent activity changes, which are characteristic of SLC25A25

These approaches can be combined to create a robust protocol for specific identification of SLC25A25 among the structurally similar mitochondrial carrier proteins.

What are the optimal storage conditions for maintaining SLC25A25 antibody activity over extended periods?

To maximize SLC25A25 antibody shelf-life and activity:

• Short-term storage (up to 2 weeks):

  • Maintain at refrigerated temperatures (2-8°C)

  • Avoid repeated temperature fluctuations

  • Keep in original container protected from light

• Long-term storage:

  • Store at -20°C in small aliquots to prevent freeze-thaw cycles

  • Ensure proper sealing to prevent evaporation

  • Label aliquots with date, concentration, and number of freeze-thaw cycles

• Aliquoting protocol:

  • Prepare single-use aliquots (typically 10-20 μL)

  • Use sterile microcentrifuge tubes

  • Briefly centrifuge after thawing to collect contents at the bottom of the tube

• Freeze-thaw minimization:

  • Limit to maximum 5 freeze-thaw cycles

  • Thaw rapidly at room temperature but maintain on ice once thawed

  • Never heat to accelerate thawing

• Working solution handling:

  • Prepare fresh working dilutions on the day of experiment

  • Discard unused diluted antibody rather than re-storing

  • Keep on ice during experiment procedures

• Stabilizing additives:

  • Antibodies are supplied in PBS with 0.09% (W/V) sodium azide as a preservative

  • For antibody solutions without preservatives, consider adding glycerol (final 30-50%) for cryoprotection

Following these storage protocols will ensure maximum antibody performance in detecting SLC25A25 across different experimental applications.

What quality control measures should be implemented to verify SLC25A25 antibody performance before critical experiments?

Implement these quality control procedures before using SLC25A25 antibodies in critical experiments:

• Performance validation:

  • Run a test Western blot using positive control samples (U-937 cell line or rat cerebellum tissue)

  • Compare band intensity and specificity to reference results

  • Verify expected molecular weight (~52.7 kDa)

• Titration assessment:

  • Perform an antibody dilution series (e.g., 1:500, 1:1000, 1:2000)

  • Determine optimal signal-to-noise ratio

  • Compare current optimal dilution to historical values to detect potential degradation

• Specificity confirmation:

  • Include negative controls (non-expressing tissues/cells)

  • Run blocking peptide controls when available

  • Compare staining pattern to previous results or literature reports

• Cross-reactivity testing:

  • Test on multiple sample types when possible

  • Evaluate non-specific bands or staining

  • Compare results across species if using in cross-species applications

• Documentation protocol:

  • Maintain a logbook recording:

    • Antibody lot number

    • Date received and expiration date

    • Number of freeze-thaw cycles

    • Results of quality control tests

    • Any observed lot-to-lot variations

• Parallel antibody strategy:

  • When possible, maintain antibodies from different suppliers or targeting different epitopes

  • Compare results between different antibodies for critical findings

  • Consider using multiple detection methods for validation